Korean J Gastrointest Endosc.  2010 Mar;40(3):175-180.

Two Cases of Gastric Marginal Zone B Cell Lymphoma Treated with a Single Agent Chemotherapy

• Bae YS
• Lee KJ
• Kim DW
• Hong JH
• Yoon JB
• Bae SH
• Lee JS
• Song CS

Abstract

Gastric marginal zone B cell lymphoma of the MALT type (MALT lymphoma) is usually accompanied by a Helicobacter pylori (H. pylori) infection. Most gastric MALT lymphomas regress after the eradication of H. pylori. Therefore, H. pylori eradication therapy is an effective first-line treatment for gastric MALT lymphoma. A second-line treatment for patients who fail to respond to eradication therapy, including radiotherapy and chemotherapy, produces a good response and survival rate. We encountered 2 cases of H. pylori eradication-resistant gastric MALT lymphoma, which were treated with cyclophosphamide monotherapy. A complete response was obtained in both cases after a treatment duration of 3 months and remission continued for 15 and 18 months, respectively. Treatment-related toxicity was mild. Oral monochemotherapy might be an alternative, effective and safe treatment modality for patients with gastric MALT lymphoma who are resistant to H. pylori eradication therapy.

Keyword

Stomach; Marginal zone; MALT; Cyclophosphamide

MeSH Terms

Cyclophosphamide
Helicobacter pylori
Humans
Lymphoma, B-Cell, Marginal Zone
Stomach
Survival Rate
Cyclophosphamide